

September 7, 2018

Dominic G. Piscitelli  
Chief Financial Officer  
AnaptysBio, Inc.  
10421 Pacific Center Court, Suite 200  
San Diego, CA 92121

Re: AnaptysBio, Inc.  
Form 10-K for the Fiscal Year Ended December 31, 2017  
Filed March 5, 2018  
File No. 001-37985

Dear Mr. Piscitelli:

We have limited our review of your filing to the financial statements and related disclosures and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response.

After reviewing your response to these comments, we may have additional comments.

Form 10-K for the Fiscal Year Ended December 31, 2017

Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations  
Results of Operations  
Comparison of Years Ended December 31, 2017 and 2016  
Research and Development Expenses, page 71

1. Please provide us an analysis of research and development expenses incurred for each year presented by product candidate. Consider providing us proposed disclosure to be included in future periodic reports to improve your disclosure.  
Item 15. Exhibits, Consolidated Financial Statement Schedules, page 104

2. Please amend your filing to provide new certifications filed as Exhibits 31.1 and 31.2 to conform exactly to that provided in Item 601(b)(31) of Regulation S-K as it relates

Dominic G. Piscitelli  
AnaptysBio, Inc.  
September 7, 2018  
Page 2

to internal controls over financial reporting (ICFR). In this regard, the introductory sentence in paragraph 4 should refer to ICFR as defined in the Exchange Act and certification 4(b) should discuss your obligations related to ICFR. Similarly, please amend the 10-Qs for the quarterly periods ended March 31, 2018 and June 30, 2018.

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Vanessa Robertson at 202-551-3649 or Mary Mast at 202-551-3613 with any questions.

FirstName LastNameDominic G. Piscitelli  
Comapany NameAnaptysBio, Inc.

Sincerely,  
Division of  
Office of

Corporation Finance  
September 7, 2018 Page 2  
Healthcare & Insurance  
FirstName LastName

